1.  

論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
掲載誌名	正式名：British journal of cancer 略　 称：Br J Cancer ISSNコード：1532-1827(Electronic)0007-0920(Linking)
掲載区分	国外
巻・号・頁	119(1),pp.19-26
著者・共著者	Chau Ian, Park Joon Oh, Ryoo Baek-Yeol, Yen Chia-Jui, Poon Ronnie, Pastorelli Davide, Blanc Jean-Frédéric, Kudo Masatoshi, Pfiffer Tulio, Hatano Etsuro, Chung Hyun Cheol, Kopeckova Katerina, Phelip Jean-Marc, Brandi Giovanni, Ohkawa Shinichi, Li Chung-Pin, Okusaka Takuji, Hsu Yanzhi, Abada Paolo B, Zhu Andrew X
発行年月	2018/07
概要	BACKGROUND:Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH.METHODS:Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed.RESULTS:Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P < 0.0001) and to radiographic progression (HR 0.613; P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29; P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53; P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001).CONCLUSIONS:Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
DOI	10.1038/s41416-018-0103-0
PMID	29808014